Positive proof of concept that long-term cure can be achieved in AML patients through inactivation of the driver mutation comes from acute promyelocytic leukemia (APL) that is, in the vast majority of the cases, driven by the PML–RARA fusion resulting from t(15;17)(q22;q21). This evidence concerns the gene RARA and acute myeloid leukemia.